Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial (Q34491558)

2 August 2017

title

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial (English)

1 reference

2 August 2017

1 reference

1 reference

J B Vermorken

1

1 reference

2 August 2017

A M Claessen

2

1 reference

2 August 2017

H van Tinteren

3

1 reference

2 August 2017

H E Gall

4

1 reference

2 August 2017

R Ezinga

5

1 reference

2 August 2017

S Meijer

6

1 reference

2 August 2017

R J Scheper

7

1 reference

2 August 2017

C J Meijer

8

1 reference

2 August 2017

E Bloemena

9

1 reference

2 August 2017

J H Ransom

10

1 reference

2 August 2017

M G Hanna

11

1 reference

2 August 2017

H M Pinedo

12

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

2 August 2017

1 reference

2 August 2017

volume

353

1 reference

2 August 2017

issue

9150

1 reference

2 August 2017

page(s)

345-350

1 reference

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907186-4

7 January 2021

Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907186-4

7 January 2021

Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907186-4

7 January 2021

Active specific immunotherapy of established micrometastasis: effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907186-4

7 January 2021

Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907186-4

7 January 2021

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907186-4

7 January 2021

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907186-4

7 January 2021

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907186-4

7 January 2021

Follow-up in colorectal cancer patients: a cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2907186-4

7 January 2021

10.1016/S0140-6736(98)07186-4

Identifiers

DOI

1 reference

2 August 2017

1 reference